Amparo Toboso Navasa
About Amparo Toboso Navasa
Amparo Toboso Navasa is a Senior Scientist in Drug Discovery at BenevolentAI in London, United Kingdom, with extensive experience in cancer research and biotechnology.
Company
Amparo Toboso Navasa is currently employed at BenevolentAI, where she holds the position of Senior Scientist, Drug Discovery. BenevolentAI is based in London, United Kingdom, and focuses on leveraging artificial intelligence to improve the drug discovery process.
Title
Amparo Toboso Navasa is a Senior Scientist in the Drug Discovery division at BenevolentAI. In her role, she leads internal disease programs and works closely with technology teams for model development and assessment. Her contributions have led to the filing of a new use patent in one of the disease areas.
Education and Expertise
Amparo Toboso Navasa has an extensive educational background. She earned her Doctor of Philosophy (PhD) from University College London (UCL), where she studied from 2013 to 2018. Prior to that, she achieved a Master's degree from Universidad Autónoma de Madrid in 2012 and another Master's degree from Universidad de Salamanca in 2021. She also holds a Licentiate degree from Universidad de Salamanca and spent a year as an exchange student in Biotechnology at the University at Buffalo from 2009 to 2010.
Background
Before joining BenevolentAI, Amparo Toboso Navasa held several research positions. She worked as a Postdoctoral Research Associate and PhD Student at The Francis Crick Institute in London. She also served as a Scientific Officer at Cancer Research UK (CRUK) and held research assistant roles at CBMSO-CNB. Her early research experiences included positions at Centro de Investigación del Cáncer (IBMCC-FICUS) and as a JAE Intro Research Fellow in Madrid and Salamanca, Spain.
Achievements
At BenevolentAI, Amparo Toboso Navasa has made significant contributions, including leading internal disease programs which resulted in a new use patent. She is also involved in the Chronic Kidney Disease (CKD) programme as part of the collaboration team between BenevolentAI and AstraZeneca.